D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

Completed · Phase 3 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Key facts

Study ID

NCT00237809

Run by

Yale University

People needed

104

Starts

2002-09-01

Expected to finish

2012-09-01

Last updated by the study team

2017-05-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia or schizoaffective disorder
• Exclusion
• Pregnant or lactating

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States
• VA Connecticut Healthcare System — West Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.